Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2025-03-20 00:00:00 ET · period of report 2025-03-18 · accession 0001628280-25-014179 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-20 | 2025-03-18 | BLFS | DE GREEF RODERICK | Pres, CEO, Dir | A - Grant | — | +112.8K | 527.8K | +27% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-18 | A | A | 112,835 | — | 527,793 | D | — | — | (F1) The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation. |